Clinical trials: Premature Lungs
Infant, Newborn, Infant, Small for Gestational Age
Hydrocortisone for BPD
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life.
- Conditions
- Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature
- Trial name
- NCT01353313
- Testing
- Hydrocortisone
- Where
- 20 sites in United States
- Volunteers
- 800 people
- Sponsor
- NICHD Neonatal Research Network
Preterm Birth, Respiratory Distress Syndrome
Sustained Lung Inflation and Pulmonary Mechanics in Preterm Infant
Lung protection should start in the delivery room where, from the first breaths, the preterm infant can be helped to clear the lung fluid and to recruit alveolar spaces and establish the functional residual capacity (FRC).
- Conditions
- Preterm Birth, Respiratory Distress Syndrome, Lung Diseases
- Trial name
- NCT02493920
- Testing
- Sustained lung inflation, mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Respiratory Distress Syndrome, Newborn
"Effectiveness of Delivery Room Bubble CPAP in Preterm Infants With Respiratory Distress
Background When babies are born too early (preterm), their lungs are often not fully developed. They may have trouble breathing because their airways and chest are not strong enough, and their lungs don't make enough surfactant…
- Trial name
- NCT07162285
- Testing
- Delivery Room Bubble CPAP, Delivery Room Supplemental Oxygen
- Where
- Bangladesh
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Respiratory Distress Syndrome
The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
The primary objective of this study is to evaluate the safety and efficacy of lucinactant for inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32 weeks gestational age who are receiving nasal…
- Trial name
- NCT02636868
- Testing
- Lucinactant delivered via investigational delivery device, nCPAP
- Where
- 54 sites in United States, Canada and 6 more
- Volunteers
- 221 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome, Newborn
High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure for Respiratory Support of Preterm Neonates
This work is designed to: 1. Evaluate the efficacy of HHHFNC in comparison with nCPAP in preterm neonates. 2. Investigate hemodynamic changes associated with HHHFNC in comparison to nCPAP in preterm neonates during periods of…
- Trial name
- NCT04238273
- Testing
- Functional Echocardiography
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Ain Shams University
Respiratory Distress, Newborn
Effectiveness of HVNI in Preterm Infants With Moderate Respiratory Distress
Neonatal respiratory distress is a common problem in preterm infants. The application of CPAP is widely used in neonatal units as a primary mode of respiratory support for respiratory distress.
- Trial name
- NCT06436222
- Testing
- HVNI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD)
National Surveillance and Prevention of Neonatal VAP
The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born…
- Conditions
- Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
- Trial name
- NCT07109791
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Cystic Fibrosis
A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein.
- Trial name
- NCT00458341
- Testing
- Ataluren
- Where
- 3 sites in Belgium, France
- Volunteers
- 30 people
- Sponsor
- PTC Therapeutics
Premature Infants, Respiratory Distress Syndrome
Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants
Pulmonary inflammation plays an important role in the development of chronic lung disease (CLD) in preterm infants. This inflammation occurs very early in postnatal life.
- Conditions
- Premature Infants, Respiratory Distress Syndrome, Chronic Lung Disease, Bronchoalveolar Lavage Fluid
- Trial name
- NCT00146497
- Testing
- Budesonide-Surfactant
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Preterm Infant
Sustained Lung Inflation in Preterm Infants
This is a randomized controlled study to investigate the effect of application of sustained lung inflation (SLI) at birth on the respiratory outcome of preterm infants with respiratory distress syndrome.
- Trial name
- NCT03518762
- Testing
- Sustained lung inflation (SLI), Continuous positive airway pressure (CPAP)
- Where
- Egypt
- Volunteers
- 160 people
- Sponsor
- Kasr El Aini Hospital
Respiratory Distress Syndrome
Caffeine Treatment in in the Delivery Room
Background. In recent years, particular attention has been paid to all interventions that could help reduce the need for mechanical ventilation MV and, therefore, the risk of BPD.
- Trial name
- CAFROOM (NCT04044976)
- Testing
- Caffeine Citrate
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Florence
Bronchopulmonary Dysplasia
Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia
OBJECTIVES: I. Estimate the efficacy of cortisol replacement therapy during the first 12 days of life for prevention of bronchopulmonary dysplasia. II.
- Trial name
- NCT00004669
- Testing
- hydrocortisone
- Volunteers
- 40 people
- Sponsor
- National Center for Research Resources (NCRR)